Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101
Aclaris Therapeutics announced that results from a Phase 2 clinical trial evaluating two concentrations (40% and 32.5%) of its drug candidate A-101 for treatment of facial seborrheic keratosis esions have been published in the journal Dermatologic Surgery. September 19, 2017